Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:II_805

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Widyantoro, B.
Right arrow Articles by Emoto, N.
PubMed
Right arrow Articles by Widyantoro, B.
Right arrow Articles by Emoto, N.

(Circulation. 2007;116:II_805.)
© 2007 American Heart Association, Inc.


Obesity: Causes and Cardiac Risk

Abstract 3556: Diabetic Cardiac and Renal Complications are attenuated in Mice with Conditional Knockout of Endothelin-1 in Vascular Endothelial Cell

Bambang Widyantoro1; Suko Adiarto1; Naoko Iwasa1; Kazuhiko Nakayama1; Dyah W Anggrahini1; Kazuya Miyagawa1; Hidemi Nonaka1; Takashi Suzuki2; Yaz Y Kisanuki3; Masashi Yanagisawa3; Noriaki Emoto4

1 Kobe Univ Graduate Sch of Medicine, Kobe, Japan
2 Tohoku Univ Sch of Medicine, Tohoku, Japan
3 Univ of Texas Southwestern Med Cntr, Dallas, TX
4 Kobe Univ Graduate Sch of Medicine, Kobe, Japan

High plasma endothelin-1 (ET-1) level has been associated with diabetic cardiovascular and renal complications, which remained prevalent despite good glycemic control. Since endothelial dysfunction, which is characterized by enhanced ET-1 secretion, plays an important role in mediating diabetic complication, we hypothesized that disruption of ET-1 in endothelial cell will be protective against cardiac and renal complication of diabetes. To test this hypothesis, we injected streptozotocin to Vascular Endothelial cell Specific Endothelin-1 Knockout (VEETKO) mice, of which ET-1 expression in major organs including heart and kidney were reduced by 60%, and to their wild type (WT) littermates. Six months of diabetes increased systolic blood pressure (SBP) similarly in both genotypes, with DM-VEETKO mice have remained lower SBP than DM-WT mice (124±1.08 vs. 131.33±1.33 mmHg, p<0.01, n=8 each). Diabetes also exaggerated the difference in cardiac ET-1 mRNA expression between both groups. The heart of DM-VEETKO mice showed lower area of interstitial fibrosis as compared to DM-WT mice, and this is associated with lower expression of fibrotic genes (TGF-ß, CTGF and Collagen-1), higher capillary density (as measured by CD-31 staining) and higher VEGF mRNA expression. Furthermore, eight months of diabetes decreased cardiac systolic function of all mice, however, the decrease is significantly attenuated in DM-VEETKO mice (fractional shortening 45.67±0.61 vs. 38.27±2.2%, p<0.01, n=4 each). Similarly, DM-VEETKO mice also preserved renal function. Diabetes caused an increase in urinary protein excretion with the values in DM-VEETKO mice being approximately one fifth of DM-WT mice (30.12±10.09 vs. 170±23.19 mg/dl, p<0.01, n=6 each) Morphologically, DM-VEETKO mice have less glomerular fibrosis which is associated with lower expression of ICAM-1, and further leads to lower glomerular macrophage recruitment. In conclusion, these findings indicate that disruption of ET-1 in endothelial cell is significantly attenuated diabetic cardiovascular and renal complication in streptozotocin-induced diabetic mice model, and may provide additional basic rationales for the use of ET-1 blockade for the prevention of cardiac and renal complication of diabetes.





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Widyantoro, B.
Right arrow Articles by Emoto, N.
PubMed
Right arrow Articles by Widyantoro, B.
Right arrow Articles by Emoto, N.